[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-weight-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-weight-adults":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100623243","pharmacokinetic-characterization-of-tartaric-acid-in-humans-100623243",false,"NCT07394101","Pharmacokinetic Characterization of Tartaric Acid in Humans","Pharmacokinetic Characterization of Tartaric Acid in Humans: Effect of the Food Matrix (Wine, Grapes, and Juice) on Its Bioavailability","TARBIO","Inclusion Criteria:\n\n* Healthy non-smoking adults aged 20-40 years.\n* Body mass index (BMI) between 23 and 27 kg\u002Fm².\n* No history of cardiovascular, hepatic, or renal disease.\n* No adherence to any special diet for at least 4 weeks prior to the study.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Current smokers or recent ex-smokers.\n* History of cardiovascular, hepatic, or renal disorders.\n* Current adherence to any special diet or nutritional supplementation that could affect study outcomes.\n* Any condition or medication that could interfere with absorption, metabolism, or excretion of tartaric acid.\n* Participation in another clinical trial within the past 3 months.\n* Pregnancy or lactation.",true,"ALL","20 Years","40 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to characterize the pharmacokinetics (absorption, distribution, metabolism, and excretion; ADME) and oral bioavailability of tartaric acid in humans after its administration through different food matrices (red wine, fresh grapes, and grape juice). The study aims to determine whether the pharmacokinetic behavior of tartaric acid is matrix-dependent and dose-dependent in healthy adult volunteers.\n\nThe main questions it aims to answer are:\n\nDoes the food matrix (wine, grapes, or grape juice) influence the oral bioavailability of tartaric acid?\n\nAre there differences in key pharmacokinetic parameters of tartaric acid, including maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), total exposure (AUC), half-life (t1\u002F2), and urinary excretion, depending on the matrix of intake?\n\nResearchers will compare the pharmacokinetic profiles of tartaric acid after consumption in red wine, grapes, and grape juice to evaluate differences in absorption, systemic exposure, and elimination attributable to the source of intake.\n\nParticipants will:\n\nFollow a polyphenol-restricted diet prior to the study, including avoidance of grapes, wine, and related products.\n\nConsume a single standardized dose of tartaric acid administered as red wine, fresh grapes, or grape juice after an overnight fast.\n\nProvide blood samples at multiple time points over a 24-hour period to determine plasma tartaric acid concentrations.\n\nCollect urine samples over 24 hours for assessment of tartaric acid excretion.\n\nConsume standardized low-polyphenol meals under controlled conditions during the study day.",[29,30,31],"Healthy Adult Participants","Non-smoking, Healthy Adults","Normal Weight Adults",[33,34,35,36,37,38],"Tartaric acid","Pharmacokinetics","Bioavailability","Food matrix effect","Wine","Healthy volunteers","NOT_YET_RECRUITING","2026-02-02",{"date":42,"type":43},"2026-02-06","ACTUAL",{"date":45,"type":23},"2026-04",{"date":47,"type":23},"2026-05",{"name":49,"class":50},"Fundacion Clinic per a la Recerca Biomédica","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":77,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100543413","individual-factors-related-to-chronic-low-grade-inflammation-and-cardiometabolic-disease-risk-100543413","NCT06355544","Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk","Integrative and Personalized Lifestyle Approach to Reduce Low-Grade Inflammation in People at Risk of Cardiometabolic Diseases","PINEAPPL","Inclusion Criteria:\n\n* Male or female between the ages of 18 and 70 included,\n* One of the following two criteria:\n* Clinically at-risk group Body Mass Index between 25 (included) and up to 35 kg\u002Fm2 (excluded)\n* Non-clinically at-risk group Body Mass Index between 18.5 (included) and up to 25 kg\u002Fm2 (excluded) and absence of metabolic syndrome criteria\n* Subject covered by social security or a similar system.\n* Ability to use a mobile phone application on a daily basis (food intake).\n* Subject, after being informed of the contents of this study, fully understanding and accepting its purpose; and able to personally sign a written informed consent\n\nExclusion Criteria:\n\n* Subject with diagnosed inflammatory disease or infection-related inflammation (viral or bacterial) or medical history (viral) within the last 2 months:\n* Rheumatoid arthritis, reactive or psoriatic arthritis (non-osteoarthritis)\n* Inflammatory bowel disease (IBD) (Crohn\\'s disease or ulcerative colitis) or irritable bowel syndrome\n* Systemic lupus erythematosus\n* Uncontrolled psoriasis\n* Viral hepatitis or ongoing viral infection\n* Seasonal virus (influenza-like illness)\n* Subjects who have taken antibiotics in the last 2 months\n* Subject under treatment within the last 2 months of an:\n* Antiviral (for HIV, hepatitis, influenza, chickenpox\u002Fshingles)\n* Oral, topical, or injectable treatment of a drug that modulates the inflammatory response (e.g. Corticosteroid, non-steroidal anti-inflammatory drugs (e.g. ibuprofen, diclofenac, celecoxib, naproxen, aspirin, etc.)\n* Dietary supplement that can modulate the inflammatory response (e.g.\n* Omega 3 fatty acid, curcuma\u002Fturmeric, probiotic, prebiotics)\n* Subject with diabetes (type 1 or 2) known treated prior to the inclusion visit (specifically subjects recently diagnosed or diagnosed with diabetes at the time of the laboratory assessment may be retained in the study if they are not taking anti-diabetic treatment): i.e. exclusion of subject with diabetes diagnosed with fasting blood glucose ≥ 126 mg\u002FdL (7.0 mmol measured twice\u002FL OR glycated hemoglobin ≥ 6.5% (48 mmol\u002Fmol) AND anti-diabetic therapy (metformin, GLP-1 receptor agonist, insulin, sulphonylurea, alpha-glucosidase inhibitor)\n* Subject with severe or unstable hepatic, renal, cardiovascular, respiratory, endocrine, or metabolic disorders or cancer diagnosed with or without treatment\n* Subject suffering from gastrointestinal disorders resulting in the use of laxatives or drugs for intestinal transit (e.g., loperamide) in the last 2 months.\n* Subject with a complication or procedure in the last 2 months that could result in inflammation\n* Minor or acute tendonitis, sprain, or contusion\n* Severe contusion (e.g. Bone contusion)\n* Major or invasive surgery\n* Subject in a situation that, in the opinion of the investigator, could interfere with optimal participation in the present study or pose a particular risk to the subject.\n* Subject currently participating in an interventional clinical study\n* Subject not affiliated to the Social Security scheme\n* Subject who did not comply with the exclusion period of the study in which they would have previously participated\n* Subject not being able to use the internet","18 Years","70 Years",{"count":63,"type":23},3000,"OBSERVATIONAL","The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.\n\nThe main questions it aims to answer are:\n\n* Whether it is possible to predict low-grade inflammation\n* What are the medical, biological, and lifestyle variables related to low-grade inflammation?\n\nParticipants will be asked to:\n\n1. Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples.\n2. Complete questionnaires and collect a stool sample at home.",[67,68,69,70,71,31,72,73,74,75,76],"Overweight","Obesity","Metabolic Syndrome","Healthy","Low-grade Inflammation","Risk Factor, Cardiovascular","Hypertension","Hypercholesterolemia","Abdominal Obesity","Metabolically Healthy Controls",[78,79,80,81,82,83],"nutrition","microbiome","lifestyle factors","low-grade inflammation","personalized nutrition","precision nutrition","2024-04-04",{"date":86,"type":43},"2024-04-09",{"date":88,"type":23},"2024-04",{"date":90,"type":23},"2026-06-30",{"name":92,"class":93},"Integrative Phenomics","INDUSTRY"]